Client News

Formycon Increases Bond Volume Following Oversubscription – Bond 2025/2029 with a Volume of EUR 70 Million Successfully and Entirely Placed

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Formycon Receives EU Approval for FYB203 (aflibercept), a Biosimilar to Eylea®, under the Brand Names AHZANTIVE® and Baiama®

Strong Demand for Formycon 2025/2029 Bond Leads to Early Closing of Subscription Period

Mallia to Showcase Innovative sCD83-Based Approach for Hair Growth at HairS‘25 Symposium

Formycon Bond 2025/2029: Public Subscription now also Possible via Deutsche Börse

Formycon AG: Subscription Period for 2025/2029 Corporate Bond has Started

Formycon Plans Public Corporate Bond Issuance to Support Next Growth Phase within Attractive Biosimilar Markets

AFYREN Begins New Phase of Industrial Strategy as First Plant AFYREN NEOXY Achieves Continuous Production

MIG Capital Announces €50 Million in Series A Funding for Look Up